Windward Bio AG is a Switzerland-based company primarily engaged in the biotechnology and biopharmaceutical industry. The Company focuses on the development of ultra-long-acting antibody medicines for immunological, respiratory, and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. Their key product is WIN378, which is a monoclonal antibody therapeutic that targets thymic stromal lymphopoietin (TSLP). It aims to reduce inflammation associated with respiratory diseases and provide longer dosing intervals for patients. The Company is also developing WIN027, a bispecific antibody targeting TSLP and interleukin-13 (IL-13) for immunological disorders.
äŒæ¥ã³ãŒãWWB
äŒç€ŸåWindward Bio AG
äžå Žæ¥Nov 13, 2026
æé«çµå¶è²¬ä»»è
ãCEOãSantarelli (Luca)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«- -
æ¬ç€Ÿæåšå°Aeschenplatz 6
éœåžBASEL
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœSwitzerland
éµäŸ¿çªå·4052
é»è©±çªå·41615517575
ãŠã§ããµã€ãhttps://windwardbio.com/
äŒæ¥ã³ãŒãWWB
äžå Žæ¥Nov 13, 2026
æé«çµå¶è²¬ä»»è
ãCEOãSantarelli (Luca)